NCT02850939 is a NA clinical trial of Mobile phone app + patient navigation in Breast Cancer, sponsored by The University of Texas Health Science Center at San Antonio.

Who is sponsoring NCT02850939?

NCT02850939 is sponsored by The University of Texas Health Science Center at San Antonio.

What drugs are being tested in NCT02850939?

Interventions in NCT02850939: Mobile phone app + patient navigation.

What condition does NCT02850939 study?

NCT02850939 studies Breast Cancer.

Is NCT02850939 still recruiting?

NCT02850939 is currently completed. Last updated 7 May 2024.

Last reviewed 2024-05-07 · How we verify

NCT02850939

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Improving Adherence to EHT Among Breast Cancer Patients

Completed NA Last updated 7 May 2024

What this trial tests

NA trial testing Mobile phone app + patient navigation in Breast Cancer in 108 participants. Completed in 30 September 2022.

Timeline

3 May 2021

Primary endpoint
31 March 2022

30 September 2022

Quick facts

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	108
Start date	3 May 2021
Primary completion	31 March 2022
Estimated completion	30 September 2022
Sites	1 location across United States

Drugs / interventions tested

Mobile phone app + patient navigation

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

The University of Texas Health Science Center at San Antonio

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adjuvant endocrine hormonal therapy (EHT) is highly effective and appropriate for nearly all breast cancer patients with hormone receptor-positive tumors, which represent 75% of all breast cancer diagnoses. Long-term use of EHT reduces cancer recurrence rates and cuts the risk of death nearly in half during the second decade after diagnosis, research shows. Despite the proven benefits, about 33% of women who are prescribed EHT do not take their medication as prescribed (less than 80% take their daily dosage) and are thus at higher risk of recurrence and death. This educational randomized controlled study will develop and pilot-test a bilingual, culturally tailored, personalized, interactive mobile application (app) in combination with patient navigation to promote and improve adherence to endocrine hormonal therapy (EHT) among breast cancer patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Patient Navigation in Cancer Treatment: A Systematic Review.
Chen M, Wu VS, Falk D, Cheatham C, et al · · 2024 · cited 72× · PMID 38581470 · DOI 10.1007/s11912-024-01514-9
Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial.
Chalela P, Munoz E, Inupakutika D, Kaghyan S, et al · · 2018 · cited 20× · PMID 30377674 · DOI 10.1016/j.conctc.2018.10.001

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other The University of Texas Health Science Center at San Antonio trials

Trials by the same sponsor.

NCT07280897 — SCIPI Implementation and Evaluation: A Multi-site Proof-of-Concept Pilot Trial · NA · not yet recruiting
NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07056699 — SGLT2i, Pioglitazone, and Ketone Production in T1D · Phase 3 · not yet recruiting
NCT06609343 — Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis · Phase 1, PHASE2 · not yet recruiting
NCT07437053 — Sarcopenia in Chronic Kidney Disease (CKD) Patients · EARLY_PHASE1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02850939 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio
Last refreshed: 7 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02850939.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing